The Trump administration advanced marijuana rescheduling through an April 2026 final order moving FDA-approved products and state-licensed medical cannabis to Schedule III, while a separate administrative hearing on broader rescheduling from Schedule I opened June 29 and closed its record by July 15. Testimony included an opposition expert conceding that marijuana meets Schedule III criteria under the Controlled Substances Act. The DEA administrative law judge’s recommendation remains pending, after which the DEA administrator will issue a final rule subject to expected litigation. A federal appeals court recently rejected challenges seeking to halt the process, and states such as Alabama have withdrawn procedural objections. These steps, following a December 2025 executive order directing expedited review, shape trader assessments of timelines for full rescheduling.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour$812,546 Vol.
31 déc. 2026
30 septembre
2%
31 décembre
22%
$812,546 Vol.
30 septembre
$739 Vol.
2%
31 décembre
$202,236 Vol.
22%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration advanced marijuana rescheduling through an April 2026 final order moving FDA-approved products and state-licensed medical cannabis to Schedule III, while a separate administrative hearing on broader rescheduling from Schedule I opened June 29 and closed its record by July 15. Testimony included an opposition expert conceding that marijuana meets Schedule III criteria under the Controlled Substances Act. The DEA administrative law judge’s recommendation remains pending, after which the DEA administrator will issue a final rule subject to expected litigation. A federal appeals court recently rejected challenges seeking to halt the process, and states such as Alabama have withdrawn procedural objections. These steps, following a December 2025 executive order directing expedited review, shape trader assessments of timelines for full rescheduling.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Marché ouvert : Feb 7, 2026, 5:04 PM ET
Volume
$812,546Date de fin
1 janv. 2027Marché ouvert
Feb 7, 2026, 5:04 PM ETRésolveur
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration advanced marijuana rescheduling through an April 2026 final order moving FDA-approved products and state-licensed medical cannabis to Schedule III, while a separate administrative hearing on broader rescheduling from Schedule I opened June 29 and closed its record by July 15. Testimony included an opposition expert conceding that marijuana meets Schedule III criteria under the Controlled Substances Act. The DEA administrative law judge’s recommendation remains pending, after which the DEA administrator will issue a final rule subject to expected litigation. A federal appeals court recently rejected challenges seeking to halt the process, and states such as Alabama have withdrawn procedural objections. These steps, following a December 2025 executive order directing expedited review, shape trader assessments of timelines for full rescheduling.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$812,546Date de fin
1 janv. 2027Marché ouvert
Feb 7, 2026, 5:04 PM ETRésolveur
0x65070BE91...The Trump administration advanced marijuana rescheduling through an April 2026 final order moving FDA-approved products and state-licensed medical cannabis to Schedule III, while a separate administrative hearing on broader rescheduling from Schedule I opened June 29 and closed its record by July 15. Testimony included an opposition expert conceding that marijuana meets Schedule III criteria under the Controlled Substances Act. The DEA administrative law judge’s recommendation remains pending, after which the DEA administrator will issue a final rule subject to expected litigation. A federal appeals court recently rejected challenges seeking to halt the process, and states such as Alabama have withdrawn procedural objections. These steps, following a December 2025 executive order directing expedited review, shape trader assessments of timelines for full rescheduling.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes